Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Advances in LAG3 cancer immunotherapeutics

Trends in cancer(2024)10.1016/j.trecan.2024.10.009Source: DataRank Database

Advances in LAG3 cancer immunotherapeutics is a research paper published in Trends in cancer (2024). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

Linked data & code

gen nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 5.26)OA: greenTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Samuel C. Butler ORCID,Creg J. Workman ORCID,Dario A.A. Vignali ORCID,Kieran Adam ORCID

Live enrichment

PubMed:39603977 PMC:PMC12047404 OpenAlex:https://openalex.org/W4404738418

National Institutes of Health

Grant: P50 CA097190

National Institute of Allergy and Infectious Diseases Division of Intramural Research

Grant: AI144422

National Institute of Allergy and Infectious Diseases Division of Intramural Research

Grant: P01 AI108545

National Cancer Institute

Grant: R35 CA263850

National Cancer Institute

Grant: T32 CA082084

National Cancer Institute

Grant: P50 CA254865

NIAID NIH HHS

Grant: R01 AI144422

Bristol-Myers Squibb Company

F-star Therapeutics

FWCI

5.26

Citation Percentile

1.0%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12047404

publisherhttps://api.elsevier.com/content/article/PII:S2405803324002486?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2405803324002486?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.trecan.2024.10.009

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCancer Research and TreatmentsHumansLymphocyte Activation Gene 3 ProteinImmune Checkpoint InhibitorsNeoplasmsImmunotherapyAntigens, CDAntibodies, BispecificAnimalsClinical Trials as TopicProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy ProtocolsT-Lymphocytes

MeSH Terms

Immune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinAnimalsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicHumansImmunotherapyNeoplasmsT-LymphocytesAntigens, CDAntibodies, BispecificProgrammed Cell Death 1 Receptor

Keywords

CancerMedicineInternal medicineBispecific antibodyImmunotherapyLag3

Sustainable Development Goals

SDG 0: Good health and well-being